What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

Open-label phase I trial shows safety and efficacy of ruxolitinib with abatacept in preventing GVHD and CRS after haplo-HCT.

Ruxolitinib treatment resulted in no engraftment failure and a 12.5% incidence of grade II acute GVHD within 100 days.
Overall survival at day 180 reached 78%, with no severe cytokine release syndrome noted during the trial.
Phase I trial observed patients with AML, ALL, MDS, and NHL receiving ruxolitinib in two treatment regimens.
Results indicate low rates of acute and chronic GVHD while monitoring non-relapse mortality associated with treatment.

Abboud et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Open-label phase I trial shows safety and efficacy of ruxolitinib with abatacept in preventing GVHD and CRS after haplo-HCT.

Ruxolitinib treatment resulted in no engraftment failure and a 12.5% incidence of grade II acute GVHD within 100 days.
Overall survival at day 180 reached 78%, with no severe cytokine release syndrome noted during the trial.
Phase I trial observed patients with AML, ALL, MDS, and NHL receiving ruxolitinib in two treatment regimens.
Results indicate low rates of acute and chronic GVHD while monitoring non-relapse mortality associated with treatment.

Abboud et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark